May 19, 2023 — Nearly half of teens given the weight loss drug semaglutide (Wegovy) managed to lose enough weight to drop below the clinical threshold for obesity, a new study shows.
By comparison, only 12.1% of adolescents with obesity given a placebo in the 68-week trial dropped below the threshold.
Semaglutide belongs to a class of drugs known as GLP-1s because they mimic the effects of glucagon-like peptide 1, a hormone made in the gut that helps people feel full.
The study, called STEP TEENS (Semaglutide Treatment Effect in People with Obesity), also shows that 74% of people in the study shifted down…
